Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares hit a new 52-week low on Thursday. The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2,000 shares. The stock had previously closed at C$0.02.
Quest PharmaTech Price Performance
The firm has a market capitalization of C$3.38 million, a P/E ratio of 0.68 and a beta of -0.75. The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The stock has a 50 day moving average of C$0.02 and a 200-day moving average of C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
